Analysis of the Therapeutic Effect of Clopidogrel Bisulfate Tablets + Aspirin Enteric-Coated Tablets on Acute Myocardial Infarction

Objective:To investigate and analyze the clinical effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on acute myocardial infarction(AMI)patients.Methods:The study period was from January 2020 to December 2023,the sample source was 82 AMI patients admitted to our hospital,grouped into an observation group(n=41)and a control group(n=41)by the numerical table method.The patients in the control group were treated with aspirin enteric-coated tablets,and the patients in the observation group were treated with aspirin enteric-coated tablets combined with clopidogrel bisulfate.The clinical efficacy,coagulation indexes,and the incidence of cardiovascular adverse events between the two groups were compared.Results:The clinical efficacy of the observation group was higher than that of the control group(P<0.05);the platelet aggregation rate(PAR)of the observation group was lower than that of the con-trol group after treatment(P<0.05),and there was no significant difference in the prothrombin time(PT)and activated partial thromboplastin time(APTT)between the two groups(P>0.05).The incidence of cardiovascular adverse events in the observation group was lower than that of the control group(P<0.05).Conclusion:The treatment effect of clopidogrel bisulfate tablets combined with aspirin enteric-coated tablets on AMI patients is remarkable.It reduces the PAR and the incidence of cardiovascular adverse events,so this treatment method should be popularized.

Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial

Treatment options for patients with relapsed extensive-stage small cell lung cancer(ES-SCLC)remain scarce.This study aims to evaluate the efficacy and safety of combining anlotinib and sintilimab plus chemotherapy as a second line or later therapy for ES-SCLC patients.This is a phase II clinical trial(ChiCTR2100049390)conducting at Shandong Cancer Hospital.Patients with ES-SCLC and received at least one prior systemic treatment were enrolled.The trial design involved a combination therapy(sintilimab,anlotinib,and nab-paclitaxel)administered over six 21-day cycles,followed by maintenance sintilimab therapy.The primary endpoint was objective response rate(ORR).Circulating tumor DNA sequencing was employed for exploratory analysis.From July 2021 to April 2023,25 eligible patients were enrolled.The confirmed ORR was 60%(95%CI:38.7–78.9%)and the DCR was 76%(95%CI:54.9–90.6%).The mPFS was 6.0 months(95%CI:5.4–9.7),and the 6-month PFS rate was 49.2%.The mOS was 13.4 months(95%CI:11.8-NR),with a 12-month survival rate of 62.2%.Treatment-related adverse events(TRAEs)of any grade occurred in 80%of patients,with the most common being fatigue(40%)and nausea(32%).TRAEs of Grade 3 or higher were reported in 12%of patients.ctDNA analysis indicated that low on-treatment blood tumor mutation burden was associated with longer PFS and OS and a potential role of KMT2D mutation in treatment resistance.This combination therapy shows promising efficacy and a manageable safety profile as a second-line or later treatment for ES-SCLC,with genomic insights providing potential biomarkers for treatment response.